Lesson 10 - Side Effects
1. Introduction
ADHD medications are among the most effective pharmacological treatments used in psychiatry, but their benefits need to be balanced against the possibility of adverse effects. For the prescriber, knowing a list of potential side effects is not enough. Good ADHD prescribing requires an understanding of which effects are common and predictable, which are dose-related or preparation-related, how they can be managed without unnecessarily abandoning an effective treatment, and which symptoms should prompt more urgent assessment or a change in treatment.
Many adverse effects encountered in routine practice are relatively mild and manageable. Reduced appetite, weight loss, sleep disturbance, headache, gastrointestinal symptoms and changes in pulse or blood pressure are familiar examples. Others are less common but clinically important, including significant cardiovascular symptoms, severe psychiatric reactions and other adverse effects that may require medication to be stopped and the patient assessed promptly. Prescribers therefore need to be able to distinguish an expected treatment-emergent effect from a potential safety signal.
Side-effect management is also closely connected to the process of titration. An apparent medication intolerance does not necessarily mean that the medication itself is unsuitable. The dose may be too high, the titration may have been too rapid, the duration of action may not suit the patient, or adverse effects may occur predominantly as the medication reaches its peak concentration or wears off. Changing the dose, timing or formulation can sometimes preserve substantial therapeutic benefit while improving tolerability.
This lesson builds on the earlier teaching on ADHD medication initiation, titration and monitoring. We will consider the adverse effects associated with stimulant and non-stimulant ADHD medications, how to assess whether a symptom is genuinely medication-related, and the practical steps available when side effects emerge. Particular attention will be given to appetite and growth, sleep, cardiovascular effects, mood and behavioural changes, tics, gastrointestinal symptoms and other clinically important adverse reactions.
The aim is not to make prescribers fearful of adverse effects, but to make prescribing safer and more confident. By the end of the lesson, learners should be better equipped to recognise side effects early, discuss them clearly with patients and families, manage common problems pragmatically, and identify the situations in which continuing medication would be inappropriate or potentially unsafe.
2. Learning Outcomes
By the end of this lesson, learners should be able to:
Identify the common and clinically important adverse effects associated with stimulant and non-stimulant ADHD medications.
Assess whether newly emerging symptoms are likely to represent medication side effects, changes in the underlying condition, comorbidity, rebound phenomena or an unrelated clinical problem.
Manage common medication side effects through appropriate adjustments to dose, timing, formulation, titration speed and supportive measures.
Recognise cardiovascular, psychiatric and other adverse effects that require prompt clinical assessment, medication interruption or discontinuation, and appropriate onward investigation.
Explain potential side effects and their management clearly to patients and families, supporting informed decision-making without creating unnecessary anxiety about treatment.
Apply an individualised risk–benefit approach when deciding whether to continue, modify, switch or stop ADHD medication.
3. The Lecture
Side Effects Are Part of Prescribing, Not a Reason to Avoid Prescribing
When we prescribe ADHD medication, we are trying to achieve a balance: meaningful improvement in ADHD symptoms and functioning with an acceptable burden of adverse effects.
That sounds obvious, but it is an important clinical principle. A patient does not need to experience absolutely no side effects for treatment to be successful. Equally, substantial improvement in concentration does not justify continuing medication when adverse effects are causing significant physical or psychological harm.
The question is therefore not simply:
“Does this medication cause side effects?”
Almost every effective medication can.
The more useful questions are:
What has changed since the medication was started or adjusted?
How severe is the adverse effect?
Is it temporally related to the medication?
Is it dose-related?
Does it occur at peak effect, throughout the day, or as the medication wears off?
Is there another plausible explanation?
Can we preserve the therapeutic benefit while reducing the adverse effect?
Is this a side effect that makes continued treatment unsafe?
This way of thinking is particularly important during titration, when therapeutic effects and adverse effects are changing simultaneously.
Establish the Timeline
Whenever a patient describes a possible medication side effect, establish the chronology before deciding what to do.
Suppose a parent tells you:
“Since starting methylphenidate, he has become really irritable.”
That information alone is insufficient.
Ask when the irritability occurs. If the child becomes irritable one or two hours after taking the medication, when its clinical effect is strongest, excessive dose or poor tolerability may be contributing. If the irritability consistently appears in the late afternoon as the medication wears off, rebound is a different possibility. If the irritability occurs throughout the day and was present before medication, the formulation changes again.
Timing often tells you more than the name of the symptom.
The same principle applies to appetite suppression, headache, nausea, anxiety, emotional blunting and sleep disturbance.
Do Not Automatically Attribute Every New Symptom to Medication
A common error during titration is to assume that anything occurring after medication initiation must have been caused by medication.
Patients with ADHD frequently have co-occurring anxiety, depression, autism, sleep difficulties, tics and other physical or mental health conditions. Children become unwell. Adults experience stressful life events. Sleep changes. Caffeine consumption varies. Other medications are started.
You therefore need to consider alternative explanations.
The reverse error is equally important: repeatedly explaining away a reproducible adverse effect despite a convincing relationship with dose changes.
A useful clinical test is to ask whether the symptom:
appeared after medication was introduced;
became worse after a dose increase;
improves as the medication wears off;
improves following dose reduction or interruption;
recurs following re-exposure.
You will not always have all of these pieces of information, but the pattern can substantially strengthen or weaken the likelihood of a medication-related effect.
Appetite Suppression and Weight Loss
Reduced appetite is one of the most familiar adverse effects associated with stimulant medication.
Patients may describe being hungry before taking medication but having very little interest in food during the period of medication effect. Parents may notice unfinished lunches, smaller evening meals or gradual weight loss.
The first step is to quantify the problem rather than simply recording “reduced appetite”.
Ask what the patient is actually eating. Review weight longitudinally. In children and young people, consider growth trajectory rather than interpreting an isolated weight measurement.
There is an important difference between:
“My appetite is slightly lower at lunchtime, but my weight is stable and I am eating normally in the evening”
and:
“I am barely eating during the day and have lost several kilograms.”
The second situation requires active intervention.
Managing Reduced Appetite
Management should initially be practical.
Taking medication with or after food may help. A substantial breakfast before the medication takes full effect can be useful. Meals or calorie-dense nutritious foods can be concentrated at times when appetite is better, including later in the day when stimulant effects have diminished.
If weight loss becomes clinically concerning, review whether the dose remains necessary and whether the duration of action of the preparation is contributing. A lower dose, different formulation or alternative medication may be appropriate.
Planned breaks from treatment may sometimes be considered, particularly where growth is a concern in a child or young person, but they should be individualised rather than applied routinely.
Do not allow “reduced appetite is common with stimulants” to become a reason for ignoring clinically significant weight loss.
Growth in Children and Young People
Growth monitoring deserves particular attention in paediatric prescribing.
Weight and height should be monitored in accordance with the patient's age and relevant guidance, and plotted appropriately. The important finding is often not a single measurement but a change in trajectory.
If a child begins crossing weight centiles following stimulant treatment, ask why.
Is appetite substantially suppressed? Is the medication duration unnecessarily long? Is the dose higher than required? Is there another medical explanation?
If height trajectory is significantly affected, treatment needs to be reviewed rather than simply continuing because ADHD symptoms have improved.
Sleep Disturbance
Sleep difficulties are common in people with ADHD even before medication is prescribed. This makes insomnia particularly easy to misinterpret.
Before changing medication, establish what the sleep problem actually is.
Is the patient unable to fall asleep?
Are they staying awake because they are no longer tired?
Are ADHD symptoms returning in the evening and making settling difficult?
Are they using phones or gaming late at night?
Are they consuming caffeine?
Did the sleep problem pre-date medication?
Most importantly, when is the medication being taken?
A stimulant taken too late in the day may predictably interfere with sleep. In that situation, changing the timing may be more sensible than abandoning a medication that is otherwise working extremely well.
A preparation with a different duration of action may also be useful.
The Rebound Problem
Not every difficult evening is caused by excessive stimulant effect.
Some patients become restless, irritable or emotionally dysregulated as medication wears off. ADHD symptoms may return quite abruptly. This is often described as rebound.
That distinction matters because reducing medication simply because “the evenings are worse” may not solve the problem.
Ask:
“What happens before the medication?”
“What happens while it is working?”
“What happens when it wears off?”
That three-part history is extremely useful during ADHD medication reviews.
Headache and Gastrointestinal Effects
Headache, abdominal discomfort and nausea can occur during ADHD treatment, particularly around medication initiation or dose adjustment.
These symptoms are often mild and may settle with time, but again, severity matters.
Check hydration, food intake and the relationship between symptoms and medication timing. A patient who skips breakfast, takes a stimulant and then eats very little until late afternoon may develop headache for several reasons.
If symptoms are persistent, severe or clearly dose-related, reconsider the dose or preparation.
Do not assume that persistent abdominal pain, vomiting or severe headache is simply an ADHD medication side effect. Significant or atypical symptoms require appropriate medical assessment.
Cardiovascular Effects
ADHD medications can affect heart rate and blood pressure. This is one reason baseline cardiovascular assessment and ongoing physical monitoring are integral to prescribing.
Small changes may occur without clinical significance. What matters is identifying sustained or clinically significant changes and, importantly, cardiovascular symptoms.
During reviews, ask about symptoms rather than relying entirely on measurements.
Relevant symptoms include palpitations, exertional breathlessness, syncope or presyncope and chest pain.
If significant tachycardia, arrhythmia or clinically important blood pressure elevation develops, the medication and the patient's cardiovascular status require review in accordance with the relevant prescribing guidance.
Chest Pain Is Different
A patient developing chest pain following stimulant initiation or a dose increase should not simply be reassured that stimulants can increase heart rate.
Chest pain requires clinical assessment.
Similarly, syncope, suspected arrhythmia or significant cardiovascular symptoms should prompt appropriate investigation and, where indicated, specialist assessment before stimulant treatment is continued or restarted.
This is an area where prescribers should resist the temptation to manage everything themselves. Recognising when specialist cardiovascular input is required is part of safe ADHD prescribing.
Palpitations and Increased Heart Rate
Patients sometimes describe becoming more aware of their heartbeat after starting stimulant medication.
Clarify what they mean by “palpitations”.
Is the heart simply beating somewhat faster?
Is it regular?
Are there sudden episodes of very rapid heart rate?
Is there associated dizziness, breathlessness, chest pain or syncope?
Measure pulse and blood pressure and interpret these alongside the clinical history.
Anxiety, caffeine, nicotine, dehydration and other stimulants can also contribute and should be considered.
Mood Changes, Irritability and Emotional Blunting
Psychological adverse effects can be more difficult to assess than physical ones.
Some patients describe becoming irritable, anxious, emotionally flat or “not themselves” on medication.
One particularly useful phrase to listen for is:
“He concentrates better, but he has lost his spark.”
That may indicate that symptom control has been achieved at an unacceptable psychological cost.
Effective ADHD treatment should generally improve functioning without suppressing the patient's personality.
Emotional blunting may indicate excessive dosing or an unsuitable preparation. Dose reduction can sometimes resolve it while preserving therapeutic benefit.
Irritability Requires Careful Timing
As discussed earlier, establish whether irritability occurs:
when medication reaches peak effect;
throughout the medication window;
as medication wears off;
or independently of medication.
These patterns may point towards different explanations and therefore different management strategies.
Anxiety
Stimulants are sometimes assumed inevitably to worsen anxiety. Clinical reality is more nuanced.
Some patients experience increased anxiety with stimulants. Others become less anxious because improved attention and executive functioning make daily life substantially easier.
If anxiety emerges during titration, establish its timing and severity and consider whether it is dose-related.
Do not automatically stop an effective ADHD medication simply because a patient has an anxiety disorder. Equally, do not continue escalating a stimulant when anxiety is clearly and reproducibly deteriorating with each increase.
The relationship needs to be assessed individually.
Agitation, Mania and Psychotic Symptoms
Rare psychiatric adverse reactions deserve particular attention because the consequences of missing them can be significant.
If a patient develops hallucinations, delusional thinking, marked behavioural disturbance, mania or another severe psychiatric change during ADHD pharmacotherapy, do not treat this as routine titration discomfort.
The medication should be reviewed urgently, with appropriate mental state and risk assessment and consideration of alternative causes.
Remember that temporal association does not prove causation. Substance use, an emerging primary psychiatric disorder, sleep deprivation and other medications may contribute.
However, continuing to increase an ADHD medication in the presence of emerging psychotic or manic symptoms would clearly be inappropriate.
Suicidality and Significant Mood Deterioration
Any emergence or worsening of suicidal thoughts requires proper clinical assessment rather than being recorded simply as a medication side effect.
Establish intent, plans, access to means, protective factors, changes from baseline and the temporal relationship with medication.
Consider the underlying psychiatric presentation as well as treatment.
Medication may need to be stopped or changed depending on the circumstances, but the immediate priority is appropriate risk assessment and management.
This is particularly important with atomoxetine, for which suicidal ideation in children and young people is a recognised safety consideration.
Tics
Tics provide another example where simplistic prescribing rules can cause problems.
Historically, clinicians were often reluctant to prescribe stimulants to patients with tic disorders. The relationship is more complicated than “stimulants cause tics”.
Tics naturally fluctuate over time, and ADHD commonly co-occurs with tic disorders. If tics emerge during treatment, establish whether they are genuinely new and whether their severity appears related to medication.
If tics are causing significant impairment and appear medication-related, dose reduction, switching medication or considering an alternative treatment may be appropriate.
The presence of a tic disorder alone does not automatically exclude stimulant treatment.
Seizures
A history of epilepsy is not automatically a contraindication to ADHD pharmacotherapy, but seizure control and relevant specialist advice may need to be considered.
If new seizures develop or established seizures clearly worsen during treatment, reassess the medication and investigate appropriately.
Do not simply label a new neurological event as a side effect without appropriate medical evaluation.
Sexual Adverse Effects and Priapism
Sexual adverse effects may not be volunteered unless clinicians ask appropriately.
Patients may experience changes in libido or sexual functioning with some ADHD medications.
A particularly important rare adverse effect associated with methylphenidate is priapism. A prolonged or painful erection requires urgent medical attention because delayed treatment can result in permanent tissue damage.
Patients should receive proportionate information about serious adverse effects without being overwhelmed by an exhaustive list of extremely rare possibilities.
Atomoxetine: A Different Adverse-Effect Profile
Atomoxetine has a different pharmacological profile from stimulants and therefore needs to be considered separately.
Common adverse effects can include gastrointestinal symptoms, reduced appetite, headache, sleep disturbance or somnolence and cardiovascular changes.
Unlike stimulants, atomoxetine generally takes longer to produce its therapeutic effect. This creates an important prescribing challenge: adverse effects may appear before the patient experiences meaningful improvement.
Do not escalate automatically simply because benefit has not yet appeared. Consider how long the patient has been taking the medication, the current dose, tolerability and expected pharmacological timeline.
Liver Injury
Clinically significant liver injury with atomoxetine is rare but important.
Routine liver-function testing is not generally required solely because someone takes atomoxetine, but symptoms suggestive of hepatic dysfunction should prompt appropriate assessment.
Potential warning symptoms include jaundice, dark urine, unexplained pruritus, right upper abdominal symptoms or other features suggestive of liver injury.
The principle is simple: rare does not mean irrelevant when the potential consequence is serious.
Guanfacine: Think About Blood Pressure and Sedation
Guanfacine commonly requires a different clinical mindset.
Sedation, fatigue, dizziness, hypotension and bradycardia can occur, particularly during initiation and dose adjustment.
A patient who says:
“I feel exhausted and dizzy every morning”
needs more than reassurance.
Check the timing of medication, blood pressure and pulse, and establish whether there are symptoms of postural hypotension.
Some sedation improves with continued treatment, but clinically significant symptoms may require slower titration or dose adjustment.
Do Not Stop Guanfacine Abruptly
This is an important prescribing point.
Abrupt discontinuation can produce increases in blood pressure and heart rate. Guanfacine should therefore normally be tapered rather than suddenly stopped, with appropriate monitoring.
This differs from many stimulant situations where medication can often be withheld without a physiological withdrawal syndrome of this type.
Medication Side Effects Can Be Preparation-Specific
One of the most useful lessons in ADHD prescribing is that intolerance of one preparation does not necessarily mean intolerance of an entire medication class.
Modified-release methylphenidate preparations differ in their release profiles. Patients can therefore experience different patterns of benefit and adverse effects even when the active drug is the same.
A patient may experience:
excellent morning control but troublesome afternoon adverse effects;
insufficient duration;
excessive peak effect;
late-day appetite suppression;
insomnia because the preparation lasts too long;
rebound because the effect falls away too abruptly.
The solution may be a different formulation rather than abandoning methylphenidate altogether.
Similarly, a patient who does not tolerate methylphenidate may tolerate lisdexamfetamine, and vice versa.
Prescribing is therefore partly about matching pharmacokinetics to the patient's day.
Dose Matters
A common mistake is to think of medication tolerability as binary:
“They tolerate methylphenidate.”
or:
“They cannot tolerate methylphenidate.”
Often the reality is:
“They tolerate 36 mg very well, but 54 mg produces unacceptable adverse effects.”
That is useful clinical information.
The optimal dose is not the highest dose the patient can physically tolerate. It is the dose that provides the best balance between symptom improvement, functional improvement and adverse effects.
If increasing from one dose to another produces minimal additional benefit but substantially more adverse effects, the higher dose has not improved treatment.
Go back.
When to Reduce, Switch or Stop
When adverse effects occur, think through a hierarchy of options.
For mild adverse effects, practical measures or observation may be sufficient.
If adverse effects appear dose-related, consider reducing the dose.
If timing is the problem, adjust administration time where appropriate.
If the release profile is unsuitable, consider a different preparation.
If one medication is poorly tolerated despite sensible adjustments, consider another ADHD medication.
If a serious adverse reaction occurs, stopping treatment and undertaking appropriate clinical assessment may be necessary.
The important point is that switching medication should not be the automatic first response to every side effect, but neither should clinicians persist indefinitely with a poorly tolerated treatment simply because it improves ADHD symptoms.
A Clinical Example
Consider a 15-year-old taking modified-release methylphenidate.
At the lower dose, concentration improves substantially at school. Appetite is mildly reduced at lunchtime, but weight remains stable.
The dose is increased because some inattentive symptoms remain.
At the higher dose, teachers report slightly better concentration. However, the young person now eats almost nothing during the day, has begun losing weight, feels emotionally flat and struggles to sleep.
What should you do?
The temptation during protocol-driven titration is to say:
“ADHD symptoms improved further, so the medication is working.”
But clinically, the higher dose is probably worse treatment.
The additional symptomatic improvement is modest, while the adverse-effect burden has increased substantially.
Returning to the previous dose may provide the better overall outcome.
This illustrates a central principle of ADHD pharmacotherapy:
We are treating the patient, not trying to drive an ADHD symptom score as low as possible.
Another Clinical Example: The Apparent Side Effect
A 32-year-old starts lisdexamfetamine and reports significant headaches after increasing the dose.
Before immediately switching medication, explore the context.
You discover that the medication has substantially reduced appetite. The patient now skips breakfast, eats almost nothing at lunchtime and has also reduced fluid intake while working.
The headache may still be related to treatment, but the mechanism may be indirect.
Address hydration and food intake, review the dose and monitor what happens.
This is considerably better prescribing than simply adding “lisdexamfetamine intolerance” to the record.
Serious Symptoms: Know When Routine Titration Ends
Most ADHD medication reviews involve relatively straightforward decisions about appetite, sleep, duration of action and dose.
Occasionally, however, a symptom changes the nature of the consultation.
Examples include:
chest pain;
syncope;
suspected arrhythmia;
severe or sustained cardiovascular abnormalities;
psychotic symptoms;
mania;
significant suicidal ideation or behavioural deterioration;
seizure;
severe allergic reaction;
symptoms suggesting significant hepatic injury;
priapism.
At this point you are no longer simply fine-tuning ADHD medication.
You are assessing a potentially significant adverse event.
The medication may need to be withheld or stopped, urgent medical or psychiatric assessment may be required, and appropriate specialist advice should be sought according to the presentation.
One of the hallmarks of a safe prescriber is knowing when ordinary titration has ended and a different level of clinical assessment is required.
Talking to Patients About Side Effects
Finally, consider how you explain risk.
There are two unhelpful extremes.
The first is to minimise adverse effects:
“These medicines are very safe. You don't need to worry.”
The second is to recite every adverse effect in the product information leaflet until the patient is frightened to take the first dose.
Neither represents good informed prescribing.
Instead, explain the common adverse effects patients are reasonably likely to encounter, the important things they should monitor, and the uncommon symptoms for which they should seek advice promptly.
Give patients a plan.
For example:
“You may notice that your appetite is lower around lunchtime. Try to eat breakfast before the medication has fully taken effect and keep an eye on your weight. If you are losing significant weight or struggling to eat, contact us rather than simply continuing until the next routine review.”
That is much more useful than simply saying:
“Methylphenidate can cause appetite suppression.”
Patients and families should know not only what might happen, but what they should do if it happens.
The Central Principle
When you review medication side effects, do not ask only:
“Are there any side effects?”
Ask:
“What is the medication doing across the whole day?”
Consider symptom control, functioning, appetite, sleep, mood, physical observations, duration of effect and what happens as the medication wears off.
Then make the decision that provides the best overall outcome.
The aim of ADHD pharmacotherapy is not maximum medication exposure or maximum symptom suppression.
It is meaningful functional improvement with a level of adverse effects that is safe and acceptable to the individual patient.
4. Clinical Perspective
Clinical Pearls
One of the most useful habits in ADHD prescribing is to ask not simply whether a side effect is present, but when it occurs. Appetite suppression at lunchtime, irritability at peak effect, emotional dysregulation as medication wears off and insomnia following a late dose all tell you something different. The timing of an adverse effect can often point towards the solution.
Do not aim for complete elimination of every ADHD symptom if achieving this requires an unacceptable dose. A patient who is functioning substantially better on a moderate dose with minimal adverse effects may be better treated than someone with slightly greater symptom reduction who cannot eat, sleep or feels emotionally blunted.
Remember that side effects are frequently dose-dependent. If a patient was doing well before the most recent increase, reducing back to the previous dose is often a sensible first intervention. The fact that a higher dose exists does not mean that the patient needs it.
Preparation matters as well as dose. Poor tolerability of one modified-release preparation does not necessarily mean that the patient cannot tolerate that active medication. Differences in release profile and duration can have considerable clinical consequences.
Practical Tips for Everyday Practice
During titration, routinely ask about appetite, weight, sleep, mood, anxiety, irritability, cardiovascular symptoms and any other new physical or psychological symptoms. In children and young people, ask about functioning across the whole day rather than concentrating only on school performance.
If appetite is reduced, establish what the patient is actually eating and review weight longitudinally. “Reduced appetite” with stable growth and good evening intake is very different from progressive weight loss.
If sleep deteriorates, check medication timing before prescribing something for sleep. Also ask about caffeine, energy drinks, screen use, sleep routine and whether insomnia was present before treatment.
If irritability occurs, determine whether it happens while the medication is active or as it wears off. Treating rebound as excessive dosing, or excessive dosing as rebound, can lead you in completely the wrong direction.
Encourage patients to contact the prescribing service if significant adverse effects develop rather than waiting until their next scheduled review. Patients should understand which symptoms can reasonably be monitored and which require more prompt assessment.
Common Pitfalls and Misconceptions
A frequent mistake is assuming that every symptom appearing during titration is caused by medication. ADHD treatment often begins against a background of anxiety, sleep difficulties, emotional dysregulation, tics and other comorbidities. Establish the baseline and look for a convincing temporal relationship.
The opposite mistake is equally problematic: continuing to increase medication despite a clear pattern of worsening adverse effects because the ADHD symptoms have not completely disappeared.
Another misconception is that experiencing a side effect means the medication has “failed”. Mild adverse effects may settle, and many can be managed by changing dose, timing or preparation.
Do not assume that stimulants invariably worsen anxiety or tics. These relationships are more complex and require individual assessment.
Similarly, do not regard normal pulse and blood pressure measurements as a substitute for asking about cardiovascular symptoms. A patient describing new chest pain, syncope or significant palpitations requires appropriate clinical assessment even if previous observations were normal.
Advice for Newly Qualified Prescribers
Early in your prescribing career, there can be a tendency to follow titration schedules too rigidly. Remember that a titration schedule is a framework, not a target.
You do not have to increase the dose simply because the next step has been planned.
If the patient is doing well, pause and ask what you are trying to improve by increasing further. If the likely additional benefit is small but adverse effects are already emerging, remaining at the current dose may be the better decision.
Equally, do not feel that you have to solve every adverse effect by adding another medication. Before treating stimulant-related insomnia with a sleep medication, for example, consider whether the stimulant dose, timing or duration is the real problem.
When you are uncertain about a potentially serious adverse effect, seek senior or specialist advice. Caution around an unusual cardiovascular, neurological or psychiatric presentation is good prescribing, not a lack of confidence.
Know Your Baseline
Good side-effect assessment starts before the first prescription.
If a patient already experiences headaches three times per week, has longstanding insomnia, frequently feels anxious and has occasional motor tics, document this before treatment. Otherwise, when these symptoms are reported during titration, it may be difficult to determine whether anything has actually changed.
Baseline physical observations and a good clinical history therefore do more than establish whether medication can safely be started. They provide the comparator against which later adverse effects can be interpreted.
Do Not Treat the Numbers in Isolation
Physical monitoring is essential, but clinical context remains important.
A single elevated pulse or blood pressure reading does not necessarily establish a medication adverse effect. The patient may have rushed to the appointment, consumed caffeine or be highly anxious. Repeat unexpected measurements appropriately and consider the overall pattern.
Conversely, repeated abnormalities should not be dismissed because the patient feels well.
Look at trends.
The same principle applies to weight. One measurement tells you relatively little; the trajectory is much more informative.
When Clinical Judgement Becomes Particularly Important
Some situations cannot be managed safely by following a simple algorithm.
A patient may have excellent symptom improvement but clinically significant weight loss.
A child may have substantially improved school functioning but become emotionally flat.
An adult may experience mild palpitations but consider the medication transformative.
A patient with pre-existing anxiety may initially become more anxious during titration but subsequently settle.
Another patient may develop subtle symptoms that raise concern about emerging mania or psychosis.
These situations require an individual risk–benefit assessment rather than a predetermined rule.
Ask yourself three questions:
How important is the benefit?
How significant is the harm?
Can I preserve the benefit while reducing the harm?
That framework resolves a surprising number of difficult prescribing decisions.
Recognise the Red Flags
Most side effects can be discussed during routine titration. Some symptoms should change your level of concern.
New chest pain, syncope, suspected arrhythmia, significant cardiovascular abnormalities, seizures, psychotic symptoms, mania, severe behavioural deterioration, significant suicidal ideation, severe allergic reactions, suspected significant liver injury or priapism should not be managed as ordinary titration problems.
Depending on the presentation, medication may need to be withheld or stopped and appropriate urgent medical, psychiatric or specialist assessment arranged.
A particularly important principle is that a stimulant should not simply be restarted after significant cardiovascular symptoms until the concern has been appropriately assessed and it is clinically safe to do so.
Listen to the Patient's Description of Themselves
Some of the most clinically useful information will not appear on a rating scale.
“I can concentrate, but I don't feel like myself.”
“I don't laugh anymore.”
“I feel wired rather than focused.”
“It works brilliantly until four o'clock and then everything falls apart.”
“I don't notice anything happening, but suddenly I can finish things.”
These descriptions can tell you a great deal about dose, tolerability and duration of action.
Rating scales can support prescribing decisions, but they cannot replace a careful conversation.
The Prescriber's Mindset
The most effective ADHD prescribers are neither overly cautious nor overly aggressive with medication.
They are curious.
When something changes, they ask why.
They consider dose, timing, preparation, pharmacology, baseline symptoms, comorbidity and alternative explanations before making the next decision.
And when the medication is providing substantial benefit, they look for ways to preserve that benefit safely rather than abandoning treatment at the first difficulty.
At the same time, they recognise when an adverse effect has crossed the line from an inconvenience of treatment to an unacceptable or potentially dangerous harm.
That balance — maintaining therapeutic benefit while continually reassessing safety and tolerability — is at the heart of high-quality ADHD prescribing.
5. Summary
ADHD medications are generally well tolerated, but safe prescribing requires active recognition, assessment and management of adverse effects throughout treatment. The aim is not simply to maximise symptom reduction, but to achieve meaningful functional improvement while maintaining acceptable physical and psychological tolerability.
Common adverse effects include reduced appetite, weight loss, sleep disturbance, headache, gastrointestinal symptoms, cardiovascular changes and alterations in mood or behaviour. Their clinical significance depends on severity, persistence and impact on the individual patient.
When a possible side effect emerges, establish its timing in relation to medication administration, peak effect, dose changes and medication wearing off. Consider the patient's baseline symptoms and alternative explanations before assuming that medication is responsible.
Many adverse effects can be managed without abandoning an otherwise effective treatment. Depending on the problem, options may include practical measures, slower titration, dose reduction, changing the timing of administration, using a different formulation or switching to another medication.
In children and young people, appetite, weight and growth require particular attention. Longitudinal trends are more informative than isolated measurements, and clinically significant changes in weight or growth trajectory should prompt active review.
Cardiovascular monitoring should include both physical observations and enquiry about symptoms. Chest pain, syncope, suspected arrhythmia or other significant cardiovascular symptoms require appropriate clinical assessment rather than routine titration management.
Prescribers should also recognise important psychiatric and neurological warning signs. Psychotic symptoms, mania, significant suicidal ideation, seizures or severe behavioural deterioration require prompt assessment and reconsideration of treatment.
Different ADHD medications have different adverse-effect profiles. Atomoxetine requires awareness of issues including gastrointestinal effects, cardiovascular changes, suicidal ideation in children and young people and rare liver injury. Guanfacine may cause sedation, hypotension and bradycardia and should not normally be stopped abruptly because of the risk of increases in blood pressure and heart rate.
The optimal dose is not the highest tolerated dose. If increasing medication produces only modest additional benefit but substantially greater adverse effects, returning to a lower dose may represent better treatment.
Most importantly, side-effect management should be individualised. Good ADHD prescribing involves continually balancing benefit against harm, listening carefully to the patient's experience and recognising when a routine titration problem has become a clinical safety concern.
6. Further Reading
The following resources are recommended for learners who wish to consolidate their understanding of adverse effects, tolerability and safety monitoring during ADHD pharmacotherapy.
NICE Guidance
National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE Guideline NG87. London: NICE; 2018, updated 2025.
This should be the principal UK reference for this lesson. Particular attention should be given to the sections on dose titration, monitoring effectiveness and adverse effects, cardiovascular monitoring, height and weight monitoring, management of tics, seizures, sleep disturbance and sexual dysfunction, and medication review and discontinuation. NICE emphasises titrating medication against both symptoms and adverse effects until dose optimisation is achieved.
International Clinical Guidelines
Australian ADHD Professionals Association (AADPA). Australian Evidence-Based Clinical Practice Guideline for Attention Deficit Hyperactivity Disorder. 2022, subsequently updated.
This is an excellent contemporary evidence-based guideline covering pharmacological treatment across the lifespan. The sections on starting and managing pharmacological interventions, medication choice, treatment monitoring and medication discontinuation are particularly relevant. The guideline reinforces an individualised approach in which therapeutic benefit, functioning and adverse effects are considered together.
Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines. 4.1 ed.
CADDRA provides particularly practical guidance for clinicians managing ADHD medication. Its discussion of adverse effects emphasises examining their timing, monitoring physical and psychological changes, and balancing therapeutic benefit against tolerability. It is a useful complement to NICE guidance for prescribers who want more detailed practical approaches to managing medication problems.
Key Evidence on Efficacy and Tolerability
Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
This landmark network meta-analysis compared the efficacy and tolerability of ADHD medications across children, adolescents and adults. It is particularly useful for understanding medication choice in the context of the balance between therapeutic efficacy and treatment acceptability.
Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews. 2015;11.
This major systematic review examines both the benefits and adverse effects of methylphenidate in children and adolescents. It is useful for developing a critical understanding of the evidence base underpinning one of the most commonly prescribed ADHD medications.
Practical Prescribing Resources
British National Formulary (BNF) and BNF for Children (BNFC). Current editions.
Prescribers should become accustomed to consulting the current BNF or BNFC alongside clinical guidelines. These provide practical information on contraindications, cautions, interactions, adverse effects, monitoring requirements and prescribing information for individual ADHD medications.
Electronic Medicines Compendium (eMC). Summaries of Product Characteristics for individual ADHD medicines.
The Summary of Product Characteristics should be consulted when detailed information is required about a particular preparation, including uncommon and rare adverse reactions, contraindications, interactions and manufacturer-specific safety information.
Suggested Focus for Further Study
When reviewing these resources, learners should concentrate particularly on:
distinguishing common and manageable adverse effects from clinically significant safety signals;
cardiovascular effects and appropriate responses to abnormal pulse, blood pressure or cardiovascular symptoms;
appetite suppression, weight loss and growth monitoring;
sleep disturbance and the influence of medication timing and duration;
psychiatric adverse effects, including mood change, psychosis, mania and suicidal ideation;
the different adverse-effect profiles of stimulants, atomoxetine and guanfacine;
when dose reduction or a change of formulation may be preferable to switching medication;
circumstances in which medication should be withheld or stopped and further assessment obtained.
The objective is not to memorise every adverse effect listed for every ADHD medication. Prescribers should instead develop a reliable framework for recognising potential medication-related problems, assessing their severity and timing, and deciding when to monitor, modify treatment, investigate further or stop medication.
7. Knowledge Check
Question 1
A 12-year-old has been taking modified-release methylphenidate for four weeks. His ADHD symptoms have improved considerably, but his parents report that his appetite is significantly reduced at lunchtime. His weight remains stable, he eats a good breakfast and his appetite returns in the evening. What is the most appropriate initial approach?
A. Stop methylphenidate immediately
B. Continue treatment while monitoring weight and supporting food intake at times when appetite is better
C. Change immediately to atomoxetine
D. Increase the methylphenidate dose
E. Prescribe an appetite stimulant
Correct answer: B
Explanation:
B is correct. Mild appetite suppression is a common adverse effect of stimulant medication. Where the medication is providing substantial benefit, weight remains stable and nutritional intake can be maintained, treatment does not necessarily need to be changed. Practical measures and continued monitoring are appropriate.
A is incorrect because appetite suppression alone does not automatically require stimulant discontinuation. The severity and clinical consequences should determine management.
C is incorrect because switching medication would be premature when the current medication is effective and the adverse effect is currently manageable.
D is incorrect because there is no indication that further dose escalation is required, and a higher dose could worsen appetite suppression.
E is incorrect because adding another medication is not an appropriate first-line response to uncomplicated stimulant-associated appetite reduction.
Question 2
A 16-year-old taking methylphenidate becomes irritable and emotionally dysregulated at approximately 5 pm each day. He functions well at school and feels calm while the medication is working. What is the most important issue to establish?
A. Whether he meets criteria for bipolar disorder
B. Whether the methylphenidate should be permanently stopped
C. Whether the symptoms coincide with the medication wearing off
D. Whether the morning dose should immediately be reduced
E. Whether an antipsychotic should be added
Correct answer: C
Explanation:
C is correct. Irritability occurring consistently as stimulant effects diminish may represent rebound. Establishing the temporal relationship between symptoms and medication action is essential before deciding how to modify treatment.
A is incorrect because bipolar disorder should not be inferred simply from late-afternoon irritability. A broader assessment would be appropriate if there were other features suggestive of mania.
B is incorrect because rebound does not necessarily mean that methylphenidate is unsuitable.
D is incorrect because reducing the morning dose without understanding the pattern could reduce effective daytime symptom control and may not resolve the evening difficulty.
E is incorrect because adding an antipsychotic without first understanding the relationship between symptoms and stimulant pharmacokinetics would be inappropriate.
Question 3
A 35-year-old develops difficulty falling asleep after their lisdexamfetamine dose is increased. What should the prescriber consider first?
A. Prescribing a hypnotic
B. Diagnosing a primary sleep disorder
C. Increasing the lisdexamfetamine further
D. Reviewing medication timing, dose, duration of effect and other contributors to insomnia
E. Stopping all ADHD treatment permanently
Correct answer: D
Explanation:
D is correct. Sleep disturbance should be assessed in context. Review when the medication is taken, whether the dose increase corresponds with the deterioration, how long its effects persist, and other factors such as caffeine, sleep routine and pre-existing insomnia.
A is incorrect because adding medication to counteract an adverse effect should not usually be the first response when modification of the causative treatment may solve the problem.
B is incorrect because a primary sleep disorder is possible but should not be assumed when insomnia has emerged following a medication change.
C is incorrect because further dose escalation could worsen a dose-related adverse effect.
E is incorrect because insomnia does not normally mean that all ADHD pharmacotherapy must be permanently abandoned.
Question 4
A patient develops new central chest pain several days after an increase in stimulant medication. What is the most appropriate response?
A. Reassure the patient that increased cardiovascular activity is expected
B. Continue the medication until the next routine review
C. Advise the patient to take the medication with food
D. Ensure the medication and cardiovascular symptoms are promptly clinically assessed, withholding stimulant treatment where appropriate pending assessment
E. Reduce the dose slightly and review in six months
Correct answer: D
Explanation:
D is correct. New chest pain in temporal association with stimulant treatment or a dose increase should not be managed as a routine minor side effect. Appropriate clinical assessment is required, and stimulant treatment should not simply be continued or restarted where a significant cardiovascular concern remains unresolved.
A is incorrect because although stimulants can affect heart rate and blood pressure, chest pain should not be dismissed as an expected treatment effect.
B is incorrect because waiting for a routine review could delay assessment of a potentially important cardiovascular problem.
C is incorrect because taking medication with food does not address the safety issue presented by new chest pain.
E is incorrect because this presentation requires assessment rather than simply a small dose adjustment and prolonged follow-up interval.
Question 5
A 10-year-old was functioning well on a moderate dose of methylphenidate. Following an increase, teachers report slightly better concentration, but the child now has substantial appetite suppression, difficulty sleeping and appears unusually emotionally flat. What is the best interpretation?
A. The higher dose is preferable because concentration has improved
B. The child should remain on the higher dose until tolerance develops
C. The previous dose may provide a better overall balance between benefit and adverse effects
D. Emotional blunting demonstrates successful ADHD treatment
E. The dose should be increased again to establish the maximum tolerated dose
Correct answer: C
Explanation:
C is correct. Dose optimisation means finding the best balance between symptom reduction, functional improvement and tolerability. A small additional improvement in concentration may not justify substantial deterioration in appetite, sleep and emotional wellbeing.
A is incorrect because ADHD treatment should not be judged solely by symptom reduction.
B is incorrect because although some adverse effects may diminish over time, significant adverse effects should not simply be tolerated without reassessing the dose.
D is incorrect. Effective treatment should not normally make a child appear emotionally suppressed or unlike themselves.
E is incorrect because titration is not an exercise in finding the highest possible dose. The objective is the optimal dose.
Question 6
Which adverse-effect pattern is particularly important to consider when prescribing guanfacine?
A. Hypertension and persistent stimulation as its principal expected effects
B. Sedation, hypotension and bradycardia
C. Severe appetite stimulation in almost all patients
D. Immediate stimulant rebound
E. Hepatic failure as a common adverse effect
Correct answer: B
Explanation:
B is correct. Guanfacine can cause sedation, fatigue, dizziness, hypotension and bradycardia, particularly during initiation and dose adjustment. Pulse and blood pressure therefore form an important part of monitoring.
A is incorrect because guanfacine generally lowers sympathetic activity rather than producing a stimulant cardiovascular profile.
C is incorrect because marked appetite stimulation is not its defining adverse-effect pattern.
D is incorrect because guanfacine is not a stimulant and does not produce the typical wearing-off pattern associated with short-duration stimulant effects.
E is incorrect because hepatic failure is not a common characteristic adverse effect of guanfacine.
An additional prescribing point is that guanfacine should not normally be stopped abruptly. Withdrawal should generally be gradual because sudden discontinuation can cause increases in blood pressure and heart rate.
Question 7
A 14-year-old taking atomoxetine develops new suicidal thoughts. What is the most appropriate response?
A. Explain that this is expected and continue treatment unchanged
B. Wait until the next routine medication review
C. Undertake a prompt clinical and risk assessment, including the temporal relationship with medication, and reconsider treatment
D. Increase the atomoxetine because untreated ADHD is the likely explanation
E. Ignore the symptoms unless there has been an act of self-harm
Correct answer: C
Explanation:
C is correct. New or worsening suicidal ideation requires proper clinical assessment. This should include severity, intent, plans, access to means, protective factors, changes from baseline and the temporal relationship with medication. Suicidal ideation is an important safety consideration with atomoxetine in children and young people.
A is incorrect because suicidal thoughts should never simply be normalised as an expected adverse effect.
B is incorrect because clinically significant deterioration in risk should not be deferred until routine follow-up.
D is incorrect because dose escalation would be inappropriate before the change in mental state has been assessed.
E is incorrect because suicidal ideation can be clinically significant even when no self-harm has occurred.
Question 8
A patient with ADHD and a longstanding tic disorder is considering stimulant treatment. Which statement is most accurate?
A. Any history of tics is an absolute contraindication to stimulant treatment
B. Stimulants invariably cause clinically significant worsening of tics
C. The presence of tics means that ADHD medication cannot be prescribed
D. Tics should be assessed longitudinally because they naturally fluctuate, and treatment decisions should consider whether any deterioration is genuinely medication-related
E. Tic severity is irrelevant during ADHD treatment
Correct answer: D
Explanation:
D is correct. Tic disorders commonly co-occur with ADHD and tics naturally fluctuate. The emergence or worsening of tics during treatment therefore does not automatically establish causation. The temporal relationship, severity and functional impact should be assessed.
A is incorrect because tic disorders are not an absolute contraindication to stimulant treatment.
B is incorrect because stimulants do not invariably worsen tics.
C is incorrect because patients with co-occurring ADHD and tic disorders can receive ADHD pharmacotherapy when clinically appropriate.
E is incorrect because significant worsening of tics may affect medication choice, dose or overall management.
Question 9
A 29-year-old reports headaches after increasing lisdexamfetamine. Further questioning reveals that since the increase they have stopped eating breakfast, rarely eat lunch and drink very little during the working day. What is the best clinical approach?
A. Record a definite allergy to lisdexamfetamine
B. Immediately conclude that the patient cannot tolerate stimulant medication
C. Explore food and fluid intake, review the dose and temporal relationship, address modifiable factors and reassess
D. Ignore the headache because headaches are common
E. Prescribe regular analgesia without reviewing the ADHD medication
Correct answer: C
Explanation:
C is correct. The headache may be directly medication-related, indirectly related through reduced food or fluid intake, or unrelated. A careful assessment allows modifiable factors to be addressed while reviewing whether the current dose remains appropriate.
A is incorrect because headache does not constitute a drug allergy.
B is incorrect because one adverse effect following a dose increase does not demonstrate intolerance of the entire stimulant class.
D is incorrect because common adverse effects still require assessment when persistent or clinically significant.
E is incorrect because routinely treating the symptom without considering its cause may unnecessarily add medication while leaving the underlying problem unresolved.
Question 10
Which statement best describes the overall approach to managing adverse effects during ADHD pharmacotherapy?
A. Medication should be stopped whenever any adverse effect occurs
B. The dose should continue to increase until the maximum licensed dose is reached
C. Symptom reduction should always take priority over adverse effects
D. The prescriber should balance therapeutic and functional benefit against adverse effects, using changes in dose, timing, formulation or medication where appropriate and recognising when urgent assessment is required
E. Mild adverse effects should never be discussed because this may increase patient anxiety
Correct answer: D
Explanation:
D is correct. Good ADHD prescribing is based on individualised optimisation. The aim is meaningful symptom and functional improvement with adverse effects that are safe and acceptable. Management may involve observation, practical interventions, slower titration, dose reduction, changes in timing or formulation, switching medication, or stopping treatment and obtaining further assessment when a serious adverse reaction is suspected.
A is incorrect because many mild adverse effects are transient or manageable and do not require treatment discontinuation.
B is incorrect because the maximum licensed dose is not a therapeutic target. The optimal dose may be considerably lower.
C is incorrect because treatment that reduces ADHD symptoms while causing unacceptable physical or psychological harm is not successful treatment.
E is incorrect because patients require appropriate information about common and important adverse effects so that they can participate in informed decision-making and know when to seek advice.
The central principle is simple: the best ADHD medication regimen is not the one that produces the greatest possible symptom suppression. It is the regimen that provides meaningful improvement in the patient's everyday functioning while remaining safe, acceptable and sustainable.
